Last10K.com

Ascendis Pharma As (ASND) SEC Filing 20-F Annual report for the fiscal year ending Tuesday, December 31, 2019

SEC Filings

ASND Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ASND Annual Reports

    20-F Annual Report March 2022
    20-F Annual Report March 2021
  • 20-F Annual Report April 2020
    • 20-F Annual Report April 2019
    20-F Annual Report March 2018
    20-F Annual Report March 2017
    20-F Annual Report April 2016
    20-F Annual Report March 2015

ASND Corporate News

Ascendis Pharma As

HISTORY TOOLS
CIK: 1612042 Ticker: ASND

View differences made from one year to another to evaluate Ascendis Pharma As's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ascendis Pharma As.

Continue

Assess how Ascendis Pharma As's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ascendis Pharma As's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 20-F Annual Report

Cover Page
Consolidated Cash Flow Statements
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Financial Position
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income
Consolidated Statements Of Profit Or Loss And Other Comprehensive Income (Parenthetical)
Contract Liabilities
Contract Liabilities - Additional Information (Detail)
Critical Accounting Judgments And Key Sources Of Estimation Uncertainty
Critical Accounting Judgments And Key Sources Of Estimation Uncertainty - Additional Information (Detail)
Distributable Equity
Finance Income And Finance Expenses
Finance Income And Finance Expenses (Tables)
Finance Income And Finance Expenses - Schedule Of Finance Income And Finance Expenses (Detail)
Financial Risk Management And Financial Instruments
Financial Risk Management And Financial Instruments (Tables)
Financial Risk Management And Financial Instruments - Additional Information (Detail)
Financial Risk Management And Financial Instruments - Liquidity Risk Management (Detail)
Financial Risk Management And Financial Instruments - Schedule Of Financial Assets And Liabilities (Detail)
Financial Risk Management And Financial Instruments - Schedule Of Foreign Currency Sensitivity Analysis (Detail)
General Information
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Summary Of Goodwill (Detail)
Investment In Associate
Investment In Associate (Tables)
Investment In Associate - Additional Information (Detail)
Investment In Associate - Equity (Detail)
Investment In Associate - Schedule Of Financial Information Of Investment In Visen (Detail)
Investments In Group Enterprises
Investments In Group Enterprises (Tables)
Investments In Group Enterprises - Summary Of Investments In Group Enterprises (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Summary Of Development In Lease Liabilities (Detail)
Leases - Summary Of Expenses, Relating To Lease Activities In The Consolidated Statements (Detail)
Other Commitments And Contingencies
Other Commitments And Contingencies - Additional Information (Detail)
Ownership
Ownership - Additional Information (Detail)
Property, Plant And Equipment
Property, Plant And Equipment (Tables)
Property, Plant And Equipment - Additional Information (Detail)
Property, Plant And Equipment - Summary Of Depreciations Charges (Detail)
Property, Plant And Equipment - Summary Of Property, Plant And Equipment (Detail)
Related Party Transactions
Revenue
Revenue (Tables)
Revenue - Additional Information (Detail)
Revenue - Schedule Of Revenue Recognized In Consolidated Statements Of Profit Or Loss (Detail)
Segment Information
Segment Information (Tables)
Segment Information - Additional Information (Detail)
Segment Information - Summary Of Intangible Assets, And Property, Plant And Equipment (Detail)
Share Capital
Share Capital (Tables)
Share Capital - Additional Information (Detail)
Share Capital - Summary Of Number Of Shares (Detail)
Staff Cost
Staff Cost (Tables)
Staff Cost - Additional Information (Detail)
Staff Cost - Schedule Of Warrant Activity (Detail)
Staff Cost - Schedule Of Warrant Activity (Parenthetical) (Detail)
Staff Cost - Schedule Of Weighted Average Exercise Price And Weighted Remaining Contractual Life For Outstanding Warrants (Detail)
Staff Cost - Summary Of Fair Values For Warrant Grants (Detail)
Staff Cost - Summary Of Staff Costs Recognized In The Statement Of Profit And Loss (Detail)
Staff Cost - Summary Of Staffing Cost (Detail)
Staff Cost - Summary Of Warrant Compensation Cost (Detail)
Staff Cost - Warrant Activity - Additional Information (Detail)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Asset's Expected Useful Life (Detail)
Summary Of Significant Accounting Policies - Summary Of Lease Liabilities Recognized In The Consolidated Financial Position (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax
Tax On Profit/(Loss) For The Year And Deferred Tax (Tables)
Tax On Profit/(Loss) For The Year And Deferred Tax - Additional Information (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax - Summary Of Tax On Profit/Loss And Deferred Tax (Detail)
Tax On Profit/(Loss) For The Year And Deferred Tax - Summary Of Tax On Profit/Loss And Deferred Tax (Parenthetical) (Detail)
Ticker: ASND
CIK: 1612042
Form Type: 20-F Annual Report
Accession Number: 0001193125-20-096870
Submitted to the SEC: Thu Apr 02 2020 9:19:52 PM EST
Accepted by the SEC: Fri Apr 03 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/asnd/0001193125-20-096870.htm